Aurinia Pharmaceuticals (AUPH) Receivables (2016 - 2026)

Aurinia Pharmaceuticals has reported Receivables for 11 years, with the latest figure at $49.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 21.87% year-over-year to $49.2 million; the trailing twelve-month figure through Mar 2026 stood at $49.2 million (up 21.87% YoY), and the FY2025 full-year result was $41.5 million, up 13.44% from the prior year.
• Receivables for Q1 2026 stood at $49.2 million, up from $41.5 million in the prior quarter.
• The five-year high for Receivables was $49.2 million in Q1 2026, with the low at $13.5 million in Q4 2022.
• Historically, Receivables has averaged $30.8 million across 5 years, with a median of $30.7 million in 2025.
• Annual changes were most pronounced in 2022 — Receivables jumped 1618.62% — and 2025, when it fell 15.81%.
• Aurinia Pharmaceuticals' Receivables stood at $13.5 million in 2022, then soared by 78.44% to $24.1 million in 2023, then surged by 51.7% to $36.5 million in 2024, then gained by 13.44% to $41.5 million in 2025, then grew by 18.63% to $49.2 million in 2026.
• The last three Receivables figures came in at $49.2 million (Q1 2026), $41.5 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.